This is perhaps best demonstrated by Mosely et al, where six of the most commonly used syngeneic tumor models showed that only two (CT26 and RENCA) were sensitive to anti-CTLA-4 therapy and only one (CT26) was sensitive to anti-PD-L1 (Mosely et al, 2017); with later studies suggesting that CT26 responses to PD-L1 inhibition may depend on antibody clonality (Kumar et al, 2020) and duration/timing of treatment schedules (Schaer et al, 2018). Here, CTLA4 is linked to neoplasm.